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Lixin Zhou4, Xiuzhen Sun5, Xinghuo Tang6, Yijiang Huang7, Yunkui Zhu8 and Weili Zhang9Abstract
Objective: This clinical study was designed to evaluate the efficacy and safety of this therapy in the treatment of
respiratory and urinary infections caused by ceftriaxone-resistant bacteria in comparison with the effect of
cefoperazone/sulbactam on cefoperazone-resistant bacteria.
Methods: A total of 285 patients aged from 18 to 65 years old, with a respiratory or urinary tract bacterial infection, were
enrolled into this multicentre, open-label, controlled clinical study, and bacteria that were either ceftriaxone-resistant or
cefoperazone-resistant were isolated from the patients, whose condition had not improved after three days of treatment
with ceftriaxone or cefoperazone. To be selected for the study, bacterial cultures obtained from the patients had to be
positive before enrolment, and all of the isolates were required to be β-lactamase-positive. Of these patients, 253
completed the trial, and 263 were enrolled into the intention-to-treat (ITT) analysis. All of the 285 patients were included
in the safety analysis.
Results: The cure and effective rates were 39.55% and 85.07% in the ceftriaxone/sulbactam group and 36.43%
and 79.84% in the cefoperazone/sulbactam group; the bacterial eradication rates were 83.58% and 83.72%; and
the adverse-event rates were 7.48% and 7.80%, respectively. There were no significant differences between the
two groups (p > 0.05).
Conclusion: Ceftriaxone/sulbactam is as effective and well-tolerated as cefoperazone/sulbactam for the
treatment of intermediate and severe bacterial infections caused by resistant strains.
Keywords: Resistant bacterial infection, Ceftriaxone/sulbactam, Multicentre clinical studyIntroduction
Ceftriaxone was used in clinical practice for approximately
30 years and was the first third-generation cephalosporin
approved for the once-daily treatment of patients with
gram-positive or gram-negative bacterial infections. How-
ever, based on data obtained from the Chinese Ministry of
Health National Antibacterial Resistance Surveillance Net* Correspondence: beijia7410@163.com
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reproduction in any medium, provided the or(Mohnarin), the majority of the isolates detected (except
Streptocococcus spp., Proteus mirabilis and Salmonella
spp.) were highly resistant to ceftriaxone with a resistance
frequency ranging from 35%-70% [1].
Sulbactam is a molecule that is administered in combin-
ation with β-lactam antibiotics to overcome the effects of
β-lactamase. It is an irreversible inhibitor of β-lactamase
that binds to the enzyme and prevents it from interacting
with the antibiotic. Sulbactam is able to inhibit the most
common forms of β-lactamase and has been commercially
available in combination with either ampicillin or cefoper-
azone [2].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not only augments the activity of ceftriaxone against
β-lactamase-producing bacteria but also maintains its
cost-effectiveness (once or twice daily administration).
A number of studies have been conducted on the pharma-
cokinetics or in vitro susceptibility of this combination
[3-7]. However, few clinical trials have reported on the
effects of using this new agent for the treatment of respira-
tory and urinary infections caused by ceftriaxone-resistant
bacteria.
Our study was undertaken to evaluate the clinical effi-
cacy and safety of injection with a fixed ratio (4:1) of this
β-lactam/β-lactamase inhibitor combination, as well as a
comparison to cefoperazone/sulbactam (2:1) injection, in
the treatment of respiratory and urinary tract infections
caused by resistant bacteria. This investigation was con-
ducted at eight medical centres in China over 5 years.
Patients and methods
Study design
This multicentre, open-label, single-blinded, controlled
clinical trial was undertaken in eight Chinese teaching
hospitals from 2005 to 2009. All of the cases were of
intermediate or severe infection caused by ceftriaxone-
resistant or cefoperazone-resistant bacteria. The protocol
was approved by the appropriate ethics committees in
each hospital and conducted in compliance with the
Declaration of Helsinki.
Key inclusion criteria
The selected inpatients or outpatients ranged in age
from 18 to 65 years old. They exhibited evidence of a
respiratory or urinary tract bacterial infection that
required antimicrobial treatment for more than three
days. Their condition had not improved after three days
of treatment with ceftriaxone or cefoperazone. To be
selected for the study, bacterial cultures obtained from
the patients had to be positive before enrolment, and all
of the isolates were required to be β-lactamase-positive.
In patients selected for the treatment group, the isolates
were resistant to ceftriaxone but sensitive to ceftriaxone/
sulbactam, whereas in patients selected for the control
group, the isolates were resistant to cefoperazone but
sensitive to cefoperazone/sulbactam. An informed con-
sent statement, which was approved by the local ethical
review board, was signed before enrolment in the trial.
The diagnosis and judgment of the condition of bacterial
infection were based on the symptoms, signs and related
laboratory examinations. The patients included in the study
who suffered from respiratory tract infections (RTIs) were
required to exhibit radiographic evidence and at least two
of the following symptoms: fever (>37°C) or hypothermia,
cough with sputum, dyspnea, crackles, rales, pleuritic pain,
dullness of percussion, and leucocytosis or leucopenia.Patients suffering from urinary tract infections (UTIs) were
eligible for inclusion if they experienced at least two of the
following symptoms: fever, urinary irritation symptoms
(dysuria, frequency, and urgency), suprapubic pain, costo-
vertebral tenderness or flank pain, or the presence of more
than five leucocytes per high-power field in a centrifuged
sediment. The judgement of severity of respiratory or
urinary tract conditions was based on symptoms, signs and
laboratory examinations of the patients according to the
criteria from Practice of Internal Medicine [8].
Key exclusion criteria
Patients were excluded from the study if they had a history
of previous allergy to β-lactam antibiotics, had participated
in a new drug trial in the previous three months, had a
history of severe cardiac, renal or haematological impair-
ment, or had increased hepatic enzyme levels >2 times the
upper limit of the normal range. Patients with a terminal
malignancy or psychiatric illness, as well as women who
were pregnant or nursing, were also excluded.
Drug administration
Patients were assigned to receive intravenous injections
with either 2.5 g of ceftriaxone/sulbactam or 4.5 g of
cefoperazone/sulbactam twice daily for 7–14 days.
Assessment and monitoring
Clinical assessments, including the symptoms and signs,
of all of the patients were performed throughout the medi-
cation period. Laboratory assessments, including routine
haematology, chemistry and urinalysis profiles, electrocar-
diogram, chest X-rays and cultures of expectorated
sputum or urine were performed at the time of enrolment
and one day after the completion of the therapy. The
safety and tolerability were assessed by observation and by
volunteered reports from the patients. Adverse events
were documented with the concomitant medications.
Women of childbearing potential were required to exhibit
normal menstruation and a negative pregnancy test. The
patients with a cured or markedly improved clinical
outcome were followed up 7 days after the treatment for
microbiological, efficacy and safety assessments.
Specimens were isolated from the sputum or urine for
bacterial culture prior to the initial treatment, on the first
day of treatment and on the 7th day after the completion of
the therapy. The Kirby-Bauer disc diffusion method and
the minimum inhibitory assay (broth dilution method) were
conducted to test the susceptibility of all of the isolates to
six antimicrobials, including ceftriaxone, ceftriaxone/sul-
bactam, cefoperazone, cefoperazone/sulbactam, cefepime
and imipenem/cilastin. The judgment of microbial suscepti-
bility was determined according to the CLSI 2005–2009
guidelines, and the susceptibility rate was calculated based
on standards [9]. The minimum inhibitory concentrations
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First Affiliated Hospital of Chongqing Medical University.
The clinical efficacy was classified as follows:
 cure – all of the presenting symptoms and signs
were resolved, and the laboratory tests and clinical
procedures were normal;
 marked improvement – only one abnormality
remained;
 improvement – at least two abnormalities remained
at the termination of treatment;
 failure – clinical manifestations remained or were
aggravated after 72 h of treatment.
The proportion of the ‘cure’ and ‘marked improvement’
categories was employed to calculate the overall efficacy
rate.
The bacteriological response was evaluated as follows:
the intervention was considered to be successful if it
achieved complete eradication (elimination of the ori-
ginal causative pathogens); the intervention was consid-
ered unsatisfactory if only partial or no eradication,Evaluated for efficacy (FAS)
n=134
Treated and evaluated for safety
n=144
Dropouts and withdrawals 
n=17 (11.81%)











Figure 1 Subject disposition.superinfection or re-infection were found. The bacterio-
logical response was defined as assumed eradication if
there were no materials for culture in the patients who
had suffered from respiratory tract infection at the end
of the treatment and/or the follow-up visit.
The safety assessments were classified into five categor-
ies: ‘definitely’, ‘probably’ or ‘possibly’ drug-related, and
‘possibly’ or ‘definitely’ drug-unrelated. The proportion of
the three drug-related categories was used to calculate the
side-effect rate.Data analysis
All of the statistical analyses were performed using the
SAS software, version 6.12 (SAS Institute, Cary, N.C.,
USA). Student’s t test, χ2 or Fisher’s exact test were used
to test the hypotheses, according to the type of the vari-
ants and the patient of study. The efficacy and safety
analyses were based primarily on the full analysis set
(FAS) population, which included all of the patients who
had received at least one dose of the study medication
and had the study disease.Evaluated for efficacy (FAS)
n=129




Did not meet inclusion criteria n=10
Missed follow-up n=3
Adverse event n=1













Male, n(%) 64(44.44%) 63(44.68%)
0.9680
Female, n(%) 80(55.56%) 78(55.32%)
Mean age, years(SD) 46.00±15.86 46.47±14.49 0.9370
Mean weight, kg(SD) 59.36±11.08 59.61±11.29 0.9742
Treatment duration 8.45±3.03 8.10±3.00 0.3251
Condition
Intermediate 113 116 0.7901
Severe 31 25 0.5085
Temperature(°C) 37.19±0.79 37.04±0.77 0.0840
With underlying diseases 34 29 0.6209
Type of infection, n(%)







Urinary tract infection 0.8021




Acute cystitis 33(45.83%) 37(53.62%)
Others 6(8.33%) 6(8.70%)
SD: Standard deviation.
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Patient disposition and baseline characteristics
After screening 2250 patients for entry into the study,
144 patients were selected to receive ceftriaxone/sulbac-
tam, and 141 received cefoperazone/sulbactam (Figure 1).
Between the two groups, there were no differences in
age, gender, weight, course of disease, condition of infec-
tion, temperature before enrolment, presence of under-
lying diseases or type of infection (Table 1).
Clinical efficacy
Although the overall clinical efficacy was higher in the cef-
triaxone/sulbactam group than in the cefoperazone/sulbac-
tam group, the difference was not statistically significant.
There was a total cure rate of 39.55% (53/134) in the ceftri-
axone/sulbactam group, compared with 36.43% (47/129) of
those receiving cefoperazone/sulbactam. The efficacy rate
of each group was 85.07 and 79.84%, respectively. The cure
and efficacy rates for respiratory and urinary tract infections
in the ceftriaxone/sulbactam group were also not signifi-
cantly different. Both of the antimicrobials were equally effi-
cient against the infections caused by Gram-negative
bacteria (p > 0.05). However, the efficacy rate for thediseases caused by gram-positive bacteria in the cefopera-
zone/sulbactam group was significantly higher than that in
the ceftriaxone/sulbactam group (p < 0.05), although the
sample size was less than 10 cases (Table 2).
Microbiological efficacy
In total, 263 strains were evaluated, with 134 in the ceftri-
axone/sulbactam group and 129 in the cefoperazone/sul-
bactam group. The overall eradication rate was 83.58% in
the ceftriaxone/sulbactam group and 83.72% in the cefo-
perazone/sulbactam group. The bacteriological success
rates for the overall and for the gram-negative or gram-
positive pathogens were comparable between the treat-
ment groups at the 7-day follow-up visit (Table 3).
In the ceftriaxone/sulbactam group, there were 129
ceftriaxone-resistant Gram-negative strains isolated. The
eradication rate was 84.50% (109/129). Five ceftriaxone-
resistant gram-positive strains were isolated, including 3
Staphylococcus haemolyticus (methicillin-sensitive) and 2
Staphylococcus aureus (methicillin-sensitive). The eradi-
cation rate was 60% (3/5).
In the cefoperazone/sulbactam group, there were 120
cefoperazone-resistant Gram-negative strains isolated. The
eradication rate was 83.33% (100/120). Nine cefoperazone-
resistant gram-positive strains were isolated, including 6
Staphylococcus haemolyticus (methicillin-sensitive) and 3
Staphylococcus aureus (methicillin-sensitive). The eradica-
tion rate was 88.89% (8/9).
For the respiratory tract diseases, there were 65 strains
isolated from the ceftriaxone/sulbactam group, with a
total eradication rate of 80.00% (52/65). The eradication
rate was 75% (3/4) for the Gram-positive strains and
80.32% (49/61) for the gram-negative strains. There were
65 isolates from the cefoperazone/sulbactam group, with
a total eradication rate of 81.53% (53/65). The eradica-
tion rate was 85.71% (6/7) for the gram-positive strains
and 81.03% (47/58) for the gram-negative strains.
For the urinary tract diseases, there were 69 and 64
strains isolated from the ceftriaxone/sulbactam and cefo-
perazone/sulbactam groups, with total eradication rates
of 86.96% (60/69) and 85.94% (55/64), respectively. The
eradication rate for the gram-negative organisms was
88.24% (60/68) in the ceftriaxone/sulbactam group and
85.48% (53/62) in the cefoperazone/sulbactam group.
Only one gram-positive strain was isolated from the cef-
triaxone/sulbactam group, and it was not cleared. Two
gram-positive strains were isolated and cleared in the
cefoperazone/sulbactam group.
No significant difference was detected between the
groups in the above eradication rates (p > 0.05).
The post-therapy (day 7 follow-up visit) bacteriological
evaluation of the patients from the cured or marked im-
provement groups revealed no differences compared
with the results at the end of therapy.
Table 2 Summary of the clinical response
Ceftriaxone-sulbactam Cefoperazone-sulbactam P
Clinical response in total at the end of therapy, n(%) 134 129
Cure 53(39.55) 47(36.43) 0.6138
Cure + marked improvement 114(85.07) 103(79.84)
0.3300
Improvement + failure 20(14.93) 26(20.16)
Clinical response for RTIs at the end of therapy, n(%) 65 65
Cure 18(27.69) 13(20.00) 0.4107
Cure + marked improvement 50(76.92) 46(70.77)
0.5398
Improvement + failure 15(23.08) 19(29.23)
Clinical response for UTIs at the end of therapy, n(%) 69 64
Cure 35(50.72) 34(53.13) 0.8626
Cure + marked improvement 64(92.75) 57(89.06)
0.5513
Improvement + failure 5(7.25) 7(10.94)
Clinical response caused by gram-negative germs at the end of therapy, n(%) 129 120
Cure 53(41.09) 44(36.67) 0.5166
Cure + marked improvement 112(86.82) 94(78.33)
0.0935
Improvement + failure 17(13.18)13.18 26(21.67)
Clinical response caused by gram-positive germs at the end of therapy, n(%) 5 9
Cure 0(0.00) 3(33.33) 0.2582
Cure + marked improvement 2(40) 9(100)
0.0275
Improvement + failure 3(60) 0(0)
Clinical response in total at the day 7 follow-up visit 114 103
Continued resolution n(%) 114(100) 103(100)
Relapse n(%) 0(0) 0(0)
RTIs: Respiratory tract infections.
UTIs: Urinary tract infections.
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The K-B disc diffusion test results showed that the sensi-
tivity rates of the isolates given ceftriaxone/sulbactam and
cefoperazone/sulbactam were 84.88 and 86.73%, respect-
ively. The difference was not statistically significant.
Minimum inhibitory concentration assays were con-
ducted on all of the isolates. The results, which are expressed
as the range of minimum inhibitory concentrations and the
concentrations required to inhibit 50% and 90% of the
isolates (the latter only for isolates with more than 10
strains), are shown in Table 4. These findings suggested
that ceftriaxone/sulbactam was as active as or slightly su-
perior to cefoperazone/sulbactam against the Enterobacte-
riaceae; however, for P. aeruginosa and A. baumannii,
ceftriaxone/sulbactam was twofold less active than cefo-
perazone/sulbactam.
Drug safety
Overall, both agents were well-tolerated by the patients in
this study. Eighteen adverse events were observed in the pa-
tients receiving ceftriaxone/sulbactam (n = 18, 7.48%), and
11 were noted in the patients receiving cefoperazone/sulbactam (n = 11, 7.80%). Fifteen drug-related events were
identified in the ceftriaxone/sulbactam group (15/144,
10.42%), and 10 were identified in the cefoperazone/sulbac-
tam group (10/141, 7.09%). In the ceftriaxone/sulbactam
group, the potentially drug-related clinical adverse reactions
were as follows: rashes (1), headache (1), chest distress (1),
nausea (2), and diarrhoea (1). The laboratory abnormalities
included leucopenia (2) and hepatic dysfunction, which was
characterised by a mild increase in the level of alanine
transferase (7). In the cefoperazone/sulbactam group, 2
patients complained of rashes and 1 reported a headache.
The laboratory abnormalities were leucopenia (3) and a
slightly increased serum level of alanine transferase (4). The
majority of the adverse events were mild to intermediate
and spontaneously alleviated or recovered. There were 5
patients who discontinued the treatments due to adverse
events, among whom two were in the ceftriaxone/sulbac-
tam group (headache and severe renal haemorrhage) and
three were in the cefoperazone/sulbactam group (headache,
leucopenia and rashes). One serious adverse event was re-
ported in the ceftriaxone/sulbactam group due to nephror-
rhagia, which was confirmed to be unrelated to the study
Table 3 Summary of the microbiological response
Ceftriaxone-sulbactam Cefoperazone-sulbactam P
Microbiological response on the day after completion of therapy, n(%) 1344 129 0.9347
Eradication 112(83.58) 108(83.72)
Partial eradication/no eradication/super infection/re-infection 22(16.42) 21(16.28)
Microbiological response for gram-negative germs, n(%) 129 120 0.8361
Eradication 109(85.83) 100(84.13)
Partial eradication/no eradication/super infection/re-infection 18(14.17) 20(16.67)
Microbiological response for gram-positive germs, n(%) 5 9 0.2269
Eradication 3(60.00) 8(88.89)
Partial eradication/no eradication/super infection/re-infection 2(40.00) 1(11.11)
Microbiological response for RTIs, n(%) 65 65 1.0000
Eradication 52(80.00) 53(81.54)
Partial eradication/no eradication/super infection/re-infection 13(20.00) 12(18.46)
Microbiological response for UTIs, n(%) 69 64 1.0000
Eradication 60(86.96) 55(85.94)
Partial eradication/no eradication/super infection/re-infection 9(13.04) 9(14.06)
Microbiological response at the day 7 follow-up, n(%) 114 103 0.8300
Eradication 80(70.18) 76(73.79)
Partial eradication/no eradication/super infection/re-infection 4(3.51) 3(2.91)
Assumed eradication(no material for culture) 30(26.32) 24(23.30)
RTIs: Respiratory tract infections.
UTIs: Urinary tract infections.
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significantly between the two groups (p > 0.05).
Discussion
China has one of the world’s highest reported rates of bac-
terial resistance. For cephalosporins, the most frequently
used antimicrobials clinically, the emergence and preva-
lence of bacterial resistance, especially to the third-
generation cephalosporins, has shifted the focus to the
combination of β-lactam and β-lactamase inhibitors. The
overuse of carbapenems and the subsequent increase in
resistance to these drugs also warrants consideration of the
role of the β-lactam and β-lactamase inhibitor combin-
ation. Cefoperazone/sulbactam is a conventional combin-
ation with activity against ESBL-producing pathogens and
clinical efficacy in a variety of infections [2,10-12]. There-
fore, cefoperazone/sulbactam was chosen as the control
treatment for testing the efficacy and safety of ceftriaxone/
sulbactam, a combination recently introduced in China. To
verify the efficacy against resistant strains, all of the
enrolled patients had respiratory or urinary infections with
isolated bacteria that were resistant to ceftriaxone or
cefoperazone.
Previous studies have suggested that a once-daily dose
of ceftriaxone/sulbactam is sufficient to treat the infec-
tions caused by various organisms due to the high plasma-
MIC levels of this combination [4]. However, whenconsidering the features of bacteria and the dosage of
cefoperazone/sulbactam, to guarantee full clinical efficacy,
we chose to perform twice-daily injections of 2.5 g of
ceftriaxone/sulbactam in this trial.
Our study on infections of the respiratory and urinary
tracts further verified the clinical efficacy and safety of
ceftriaxone/sulbactam. The results showed that ceftri-
axone/sulbactam was equally as effective as cefopera-
zone/sulbactam with respect to the clinical cure rate
(36.43 vs. 39.55%), the efficacy rate (85.07 vs. 79.84%)
and the bacterial eradication rate (83.58 vs. 83.72%). In
RTIs, the clinical cure rate (27.69% in the ceftriaxone/
sulbactam group vs. 20% in the cefoperazone/sulbac-
tam group) and the efficacy rate (76.92% in the ceftriax-
one/sulbactam group vs. 70.77% in the cefoperazone/
sulbactam group) were comparable. Similar results
were observed in the treatment of UTIs. There were no
statistically significant differences in any of the rates for
the two drugs. Both drugs were more efficacious when
treating UTIs, possibly due to the higher bacterial
eradication rates. The cure rates were relatively low for
both drugs, especially when treating RTIs, and were far
lower than previously reported rates [10,11]. Recently,
the clinical response in a multicentre clinical trial of
ceftriaxone/sulbactam in lower respiratory tract infec-
tions in India indicated an average cure rate of 77.1%
(unpublished data). The lower cure rates in our study
Table 4 In vitro susceptibility of the clinical isolates to 6 antimicrobials
Isolates Cefoperazone-sulbactam Cefoperazone Ceftriaxone-sulbactam Ceftriaxone Imipenem Cefepime
MICr 32–4 128–64 32–81 28–64 8–1 16–2
E. coli(153) MIC50 16 64 8 64 1 4
MIC90 32 128 32 128 4 16
MICr 32–2 128–32 16–2 128–32 4–1 16–2
K. pneumoniae(22) MIC50 8 64 4 64 1 4
MIC90 32 128 16 128 2 8
MICr 32–4 128–32 32–8 128–64 8–2 16–2
E cloacae(18) MIC50 16 32 8 64 2 4
MIC90 32 128 32 128 4 16
MICr 32–8 128–64 16–4 128–64 4–1 8–1
E. aerogenes(13) MIC50 8 64 16 64 1 2
MIC90 32 128 32 128 2 8
Proteus spp(6) MICr 8–4 64–32 4–2 32–16 2–1 8–1
MICr 32–4 128–32 32–8 128–32 64–4 64–8
A. baumannii(12) MIC50 8 32 8 32 8 16
MIC90 16 128 32 128 64 64
MICr 32–2 128–4 32–4 128–8 64–4 32–4
P. aeruginosa(10) MIC50 8 32 16 64 4 8
MIC90 32 128 32 128 32 32
S. aureus(5) MICr 32–16 64–32 32–16 64–32 16–2 8–4
S. haemolyticus(9) MICr 32–16 64–32 32–8 64 16–2 8–4
MIC: minimum inhibitory concentration; MIC50: Minimum Inhibitory Concentration required to inhibit the growth of 50% of organisms; MIC90: Minimum Inhibitory
Concentration required to inhibit the growth of 90% of organisms; MICr: Range of MIC.
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sional inconsistence of in vitro activity (susceptible)
and clinical outcomes (suboptimal) for these isolated
resistant strains.
The in vitro susceptibility study of the isolates demon-
strated the remarkable antibacterial activity of ceftriaxone/
sulbactam, with an overall susceptibility rate of 84.88%.
The MICs of all of the microbial strains tested were sig-
nificantly reduced with ceftriaxone/sulbactam compared
with ceftriaxone alone, which is consistent with results re-
ported by other investigators [3,4,6,7]. All of the bacteria
isolated in this study were β-lactamase-positive, although
we unfortunately did not determine the specific types of
β-lactamases from these isolates. Members of the family
Enterobacteriaceae are among the most important human
bacterial pathogens. These microbes comprise approxi-
mately 65% of all Gram-negative bacteria and 47% of all of
the isolates identified in hospital laboratories in China [13].
The production of β-lactamases and the emergence and
proliferation of extended-spectrum β-lactamases (ESBLs)
are increasing the antimicrobial resistance of many species
of Enterobacteriaceae and causing the dissemination of
multidrug-resistant (MDR) strains [14,15]. CTX-M en-
zymes are the dominant ESBL type in China [16]. A previ-
ous study has demonstrated the in vitro efficacy ofceftriaxone/sulbactam against bacteria harbouring these
types of enzymes [7,17].
Notably, ceftriaxone alone does not possess adequate ac-
tivity against A. baumannii and P. aeruginosa. The com-
bination restores a degree of antimicrobial activity against
these species. Therefore, ceftriaxone/sulbactam offers a
potential alternative to cefoperazone/sulbactam for the
treatment of infection caused by these intrinsically resist-
ant species.
Both of the combinations have favourable safety records
and are well-tolerated. The patients receiving ceftriaxone/
sulbactam exhibited an insignificant increase in drug-
related clinical adverse events compared with patients
receiving cefoperazone/sulbactam (10.42 vs. 7.09%,
P = 0.3212). Among the adverse events, gastrointestinal
side effects, nervous system symptoms, hepatic function
and routine blood test abnormalities were the most fre-
quently encountered. Although one severe adverse event
of nephrorrhagia occurred in a patient with a recent pyelo-
lithotomy who had received the ceftriaxone-sulbactam
treatment, an investigation verified that the effect was
most likely unrelated to the drug itself. Nearly all of the
side effects were mild and well tolerated, which suggested
that ceftriaxone/sulbactam could be safely employed in
clinical settings for the treatment of the infections studied.
Xin et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:38 Page 8 of 8
http://www.ann-clinmicrob.com/content/12/1/38Due to the limitations of clinical trials, most of the cases
investigated were from community-acquired infections in
which the general resistance rate of bacteria is low.
This low rate contributed to the 5 years that were required
to complete this trial. Based on the characteristics of the
β-lactam/β-lactamase-inhibitor combination, ceftriaxone/
sulbactam should be used for the treatment of multidrug-
resistant bacterial infections. More data are required for
the treatment of nosocomial infections.
Conclusion
Ceftriaxone/sulbactam is as effective and well-tolerated
as cefoperazone/sulbactam for the treatment of inter-
mediate and severe bacterial infections caused by resist-
ant strains.
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